Mycophenolate mofetil in lupus nephritis

Abstract

There is an increasing body of literature suggesting the efficacy and tolerability of mycophenolate mofetil (MMF) for the treatment of lupus nephritis. The rationale for its use is based upon its successful profile as an immunosuppressive agent for prevention of allograft rejection, as well as studies in murine models of lupus which have reported improved renal function and animal survival compared to placebo. This report reviews the data regarding MMF therapy in murine lupus models, and describes the initial anecdotal experience with MMF in human lupus, especially in patients with glomerulonephritis who were unresponsive to corticosteroids and cyclophosphamide, or who had unacceptable toxicity on this standard of care regimen. The results of several nonblinded, controlled clinical trials are also described, in which MMF was compared to intravenous or oral cyclophosphamide in patients with lupus nephritis. MMF was found to be well tolerated, with most studies showing fewer infections than that associated with cyclophosphamide. Efficacy of MMF was at least equivalent to cyclophosphamide, and therefore appears to provide an alternative as a standard of care for induction and maintenance treatment of lupus nephritis.

Keywords

lupus nephritis mycophenolate mofetil SLE

Get full access to this article

View all access options for this article.

References

Allison AC , Eugui EM. Mycophenolate mofetil and its mechanisms of action . Immunopharmacology 2000; 47: 85-118 .

Corna D , Morigi M , Facchinetti D , Bertani T , Zoja C , Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease . Kidney Int 1997; 51: 1583-1589 .

McMurray RW , Elbourne KB , Lagoo A , Lal S. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus . J Rheumatol 1998; 25: 2364-2370 .

Ramos MA , Pinera C , Setien MA et al. Modulation of autoantibody production by mycophenolate mofetil: effects on (NZB × NZW) F1 mice . Nephrol Dial Transplant 2003; 18: 878-883 .

Zoja C , Benigni A , Noris M et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis . Kidney Int 2001; 60: 653-663 .

van Bruggen MC , Walgreen B , Rijke TP , Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil . J Am Soc Nephrol 1998; 9: 1407-1415 .

Jonsson CA , Svensson L , Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice . Clin Exp Immunol 1999; 116: 534-541 .

Yu CC , Yang CW , Wu MS et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice . J Lab Clin Med 2001; 138: 69-77 .

Lui SL , Tsang R , Wong D et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice . Lupus 2002; 11: 411-418 .

10.

Glicklich D , Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide . Am J Kidney Dis 1998; 32: 318-322 .

11.

Gaubitz M , Schorat A , Schotte H , Kern P. Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial . Lupus 1999; 8: 731-736 .

12.

Dooley MA , Cosio FG , Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations . J Am Soc Nephrol 1999; 10: 833-839 .

13.

Li L-S , Hu W-X , Zhou H , Liu Z-H. Clinico-pathological evaluation of mycophenolate mofetil (MMF) therapy in twenty-three cases of diffuse proliferative lupus nephritis (SLE-DPGN) . J Am Soc Nephrol 1999; 10: 172-172 (abstract 0881).

14.

Kingdon EJ , McLean AG , Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: A pilot study . Lupus 2001; 10: 606-611 .

15.

Karim MY , Alba P , Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents . Rheumatology 2002; 41: 876-882 .

16.

Riskalla MM , Somers EC , Fatica RA , McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus . J Rheumatol 2003; 30: 1508-1512 .

17.

Kapitsinou PP , Boletis JN , Skopouli FN , Boki KA , Moutsopoulos HM Lupus nephritis: treatment with mycophenolate mofetil . Rheumatology 2004; 43: 377-380 .

18.

Ferro ML , Karim MY , Abbs IC , D’Cruz DP , Khamashta MA , Hughes GRV Mycophenolate mofetil: a potential treatment for reducing proteinuria associated with membranous lupus nephritis . Arthritis Rheum 2003; 48: S588-S588 .

19.

Fu YF , Liu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine . Clin Nephrol 2001; 55: 318-321 .

20.

Buratti S , Szer IS , Spencer CH , Bartosh S , Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus . J Rheumatol 2001; 28: 2103-2108 .

21.

Bijl M , Horst G , Bootsma H , Limburg PC , Kallenberg CGM. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk . Ann Rheum Dis 2003; 62: 534-539 .

22.

Chan TM , Li FK , Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis . New Engl J Med 2000; 343: 1156-1162 .

23.

Falk RJ. Treatment of lupus nephritis - a work in progress . New Engl J Med 2000; 343: 1182-1183 .

24.

Chan TM , Wong RWS , Lau CS et al. Prolonged follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil . J Am Soc Nephrol 2001; 12: 195A-195A (abstract).

25.

Ye Z , Tan YH , Hong XP , Feng XX , Xiao XL. MMF vs CTX in the treatment of severe SLE patients . Lupus 2001; 10: S99-S99 (abstract, suppl. 1).

26.

Hu W , Liu Z , Chen H et al. Mycophenolate Mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis . Chin Med J 2002; 115: 705-709 .

27.

Ginzler EM , Aranow C , Buyon J et al. A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results . Arthritis Rheum 2003; 48: S647-S647 .

28.

Ginzler EM , Aranow C , Merrill JT , Orloff K , Henry D. Toxicity and tolerability of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) in a multicenter trial as induction therapy for lupus nephritis (LN) . Arthritis Rheum 2003; 48: S586-S586 .

29.

Naylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients . Transplantation 1997; 64: 1277-1282 .

30.

Contreras G , Pardo V , Leclercq B et al. Sequential therapies for proliferative lupus nephritis . N Engl J Med 2004; 350: 971-980 .